References
- Ducry L , StumpB. Antibody drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjugate. Chem.21(1) , 5–13 (2010).
- Barrett A , RoquesT, SmallM, SmithRD. How much will herceptin really cost? BMJ333(7578) , 1118–1120 (2006).
- Goldmacher VS , KovtunYV. Antibody–drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther. Deliv.2(3) , 397–416 (2011).
- Chen J , JaraczS, ZhaoX, ChenS, OjimaI. Antibody–cytotoxic agent conjugates for cancer therapy. Expert Opin. Drug Deliv.2(5) , 873–890 (2005).
- Beck A , HaeuwJF, WurchT, GoetschL, BaillyC, CorvaiaN. The next generation of antibody–drug conjugates comes of age. Discov. Med.10(53) , 329–339 (2010).
- Beck A , WurchT, BaillyC, CorvaiaN. Strategies and challenges for the next generation of therapeutic antibodies. Nature Rev. Immunol.10(5) , 345–352 (2010).
- Wakankar AA , FeeneyMB, RiveraJ et al. Physicochemical stability of the antibody–drug conjugate trastuzumab–DM1: changes due to modification and conjugation processes. Bioconj. Chem. 21(9) , 1588–1595 (2010).
- Fishkin N , MaloneyEK, ChariRVJ, SinghR. A novel pathway for maytansinoid release from thioether linked antibody–drug conjugates (ADCs) under oxidative conditions. Chem. Comm.47(38) , 10752–10754 (2011).
- Katz J , Janik Je, Younes A. Brentuximab Vedotin (SGN-35). Clin. Cancer Res.17(20) , 6428–6436 (2011).
- Song JJ , LeeYJ. Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily. Cell. Signal.20(5) , 892–906 (2008).
- Ryan MC , KostnerH, GordonKA et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75. Br. J. Cancer 103(5) , 676–684 (2010).
- Gerber HP , Kung-SutherlandM, StoneI et al. Potent antitumor activity of the anti-CD19 auristatin antibody–drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 113(18) , 4352–4361 (2009).
- Doronina SO , BoveeTD, MeyerDW et al. Novel peptide linkers for highly potent antibody–auristatin conjugate. Bioconj. Chem. 19(10) , 1960–1963 (2008).
- Zhao RY , WilhelmSD, AudetteC et al. Synthesis and evaluation of hydrophilic linkers for antibody–maytansinoid conjugates. J. Med. Chem. 54(10) , 3606–3623 (2011).
▪ Patents
- Seattle Genetics, Inc.: US20110070248 (2011).
- Urogenesys, Inc.: WO200061746 (2000).
- Seattle Genetics, Inc.: WO2010111018 (2010).
- Seattle Genetics, Inc.: WO2010081004 (2010).
- Seattle Genetics, Inc.: US7750116 (2010).
- Seattle Genetics, Inc.: WO2009048967 (2009).
- Seattle Genetics, Inc.: WO2009126934 (2009).
- Seattle Genetics, Inc.: WO2009052431 (2009).
- Seattle Genetics, Inc.: WO2009117531 (2009).
- Immunogen, Inc.: US20110177064 (2011).
- Immunogen, Inc.: WO2011050180 (2011).
- Immunogen, Inc.: WO2009134976 (2009).
- Biotest, AG, Immunogen, Inc.: WO2010128087 (2010).
- Biotest, AG, Immunogen, Inc., Dana-Farber Cancer Institute, Inc.: WO2009080832 (2009).
- Biotest, AG, Immunogen, Inc.: WO2009080831 (2009).
- Immunogen, Inc.: WO2009134977 (2009).
▪ Websites
- FDA: Pfizer voluntarily withdraws cancer treatment Mylotarg® from US market. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm216448.htm
- Trastuzumab emtansine. www.immunogen.com/wt/page/trastuzumab_DM1
- Genentech receives refuse to file letter from FDA for T-DM1 – new BLA expected to be submitted in mid-2012. http://phx.corporate-ir.net/phoenix.zhtml?c=97573&p=irol-newsArticle&ID=1464217&highlight
- T-DM1 significantly improved progression-free survival compared to standard of care for previously untreated HER2-positive metastatic breast cancer. http://phx.corporate-ir.net/phoenix.zhtml?c=97573&p=irol-newsArticle&ID=1609696&highlight=
- Brentuximab Vedotin. www.seagen.com/product_pipeline_sgn35.shtml
- Seattle Genetics‘ new drug price: $108k per patient. www.bizjournals.com/seattle/news/2011/08/22/seattle-genetics-new-drug-price.html
- Mechanism of cysteine-mcMMAF release from the antibody–drug conjugate SGN-75 www.seagen.com/pdf/SGN-75_AACR2010_Zhang.pdf
- SGN-75. www.seagen.com/product_pipeline_sgn75.shtml
- SGN- CD19A. www.seagen.com/product_pipeline_sgn19a.shtml
- Seattle genetics highlights ADC technology research at AACR. www.businesswire.com/news/home/20110405005752/en/Seattle-Genetics-Highlights-ADC-Technology-Research-AACR
- Lorvotuzumab mertansine. www.immunogen.com/wt/page/IMGN901b
- An antibody–maytansinoid conjugate with hydrophilic linkers: cytotoxic therapeutics with enhanced potency in vitro and in vivo. www.immunogen.com/pdf/POL%20linkers%20AACR%204%2009.pdf
- The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. www.biotest.de/shared/data/pdf/biotherapeutics/bt062_ash_poster_2008.pdf
- Safety and dose determining study of BT062 in patients with relapsed or refractory multiple myeloma. http://clinicaltrials.gov/ct2/show/NCT00723359?term=BT062&rank=2
- Product pipeline. www.immunogen.com/wt/page/pipeline
- Antibody–drug conjugate technology collaborations. www.seagen.com/collaborations_ADC.shtml